Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK is the fifth company to leave BIO in roughly a year, a group that includes Pfizer and UCB. The departures coincided with ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

Moderna’s (NASDAQ:MRNA) Q3 results confirmed on Thursday that the U.S. vaccine market for respiratory syncytial virus (RSV), ...

GlaxoSmithKline has found a replacement for head of vaccines R&D Emmanuel Hanon, who left the company for a US biotech earlier this year, hiring Phil Dormitzer from ...

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

GSK is the fifth company to leave BIO in roughly a year, a group that includes Pfizer (PFE). The departures coincided with a drop in lobbying spending from the group and other challenges, STAT says.

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster COVID-19 ...

Wednesday, GSK Plc (NYSE:GSK) reported third-quarter sales of $10.42 billion (8.01 billion Sterling Pounds), down 2% ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...